Perrigo Company AI Stock Analysis
Want to see PRGO full AI Analyst Report?
Perrigo Company (PRGO) AI Stock Analysis
Perrigo Company
(NYSE:PRGO)
The score is held back primarily by weak financial performance (deep losses, very negative margins/ROE, and balance-sheet uncertainty), partially offset by positive free cash flow. The earnings call adds a mixed-but-improving view (cost savings and portfolio simplification, but lowered 2026 outlook and high leverage). Technicals are moderately supportive with price above key longer-term averages and a positive MACD, while valuation benefits from a high dividend yield but is constrained by loss-driven negative P/E.
Perrigo Company (PRGO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.19B
- Dividend Yield
- 7.36%
- Average Volume (3M)
- 2.56M
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.96
- Revenue Growth
- -4.45%
- EPS Growth
- -3289.03%
- Country
- US
- Employees
- 8,100
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Perrigo Company Business Overview & Revenue Model
Company Description
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper res...
How the Company Makes Money
Perrigo primarily makes money by selling consumer self-care products through two main routes: (1) private-label/store-brand manufacturing and supply, and (2) branded OTC/self-care products sold under Perrigo-owned brands. For private-label, Perrigo e...
Perrigo Company Earnings Call Summary
The call presented a mixed but improving picture. Perrigo reported sequential improvement in core sales trends and operating margins, meaningful share gains in U.S. store brand OTC and European brands, progress on its Three-S plan, cost savings and a strategically important infant formula divestiture. However, Q3 sales, margins and EPS declined, the company lowered its outlook because of cautious retailer inventory positioning and continued European softness, and leverage remains elevated. The positive strategic and operational developments were offset by significant current-period financial pressures.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, core reported net sales are expected to decline 2.5%-3.6%, organic net sales to decline 2.7%-3.8%, adjusted gross margin to be 37.5%-38.5%, adjusted operating margin to be 14%-15%, and adjusted diluted earnings per share to be $2.15-$2.35; all-in, which now excludes infant formula but includes other divestitures, reported net sales are expected to decline 4.6%-5.7%, adjusted gross margin to be 37.8%-38.8%, adjusted operating margin to be 14.3%-15.3%, and adjusted diluted earnings per share expected to be between $2.25 and $2.45. For both core and all-in, net interest expense is assumed to be approximately $162 million, adjusted effective tax rate approximately 14%, and approximately 140 million diluted shares outstanding, with year-end net leverage of approximately four times adjusted EBITDA and all-in cash from operating activities as a percentage of adjusted net income expected to be in the low to mid-60% range; the Operational Enhancement Program remains on track to deliver approximately $60 million-$80 million in 2026.
Perrigo Company Financial Statement Overview
Summary
Cash flow is a stabilizer (TTM operating cash flow $241M; free cash flow $168M), but profitability is the major weakness: revenue is down slightly (TTM -1.32%) and net margin is deeply negative (-41.9%) with a widening net loss versus 2025. The balance sheet adds uncertainty due to inconsistent debt presentation across periods and very negative ROE (TTM -56.0%), keeping the overall financial profile below average despite positive FCF.
Income Statement
18Very NegativeBalance Sheet
45NeutralCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.09B | 4.25B | 4.37B | 4.66B | 4.45B | 4.14B |
| Gross Profit | 1.32B | 1.49B | 1.54B | 1.68B | 1.46B | 1.42B |
| EBITDA | -1.11B | -797.90M | 433.00M | 525.00M | 355.50M | 695.90M |
| Net Income | -1.77B | -1.43B | -171.80M | -12.70M | -140.60M | -68.90M |
Balance Sheet | ||||||
| Total Assets | 7.48B | 8.54B | 9.65B | 10.81B | 11.02B | 10.43B |
| Cash, Cash Equivalents and Short-Term Investments | 436.60M | 531.60M | 558.80M | 751.30M | 600.70M | 1.86B |
| Total Debt | 3.45B | 3.97B | 3.62B | 4.07B | 4.32B | 3.69B |
| Total Liabilities | 5.04B | 5.60B | 5.33B | 6.04B | 6.18B | 5.27B |
| Stockholders Equity | 2.44B | 2.94B | 4.32B | 4.77B | 4.84B | 5.15B |
Cash Flow | ||||||
| Free Cash Flow | 223.90M | 145.10M | 244.60M | 303.80M | 210.90M | 4.20M |
| Operating Cash Flow | 296.30M | 238.50M | 362.90M | 405.50M | 307.30M | 156.30M |
| Investing Cash Flow | 285.10M | -75.40M | 78.80M | -77.50M | -1.96B | 1.28B |
| Financing Cash Flow | -572.00M | -220.50M | -611.00M | -187.20M | 421.60M | -178.70M |
Perrigo Company Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRGO, the sentiment is Neutral. The current price of 15.76 is below the 20-day moving average (MA) of 16.06, above the 50-day MA of 15.22, and above the 200-day MA of 12.23, indicating a neutral trend. The MACD of 0.25 indicates Positive momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 47.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRGO.
Perrigo Company Risk Analysis
Perrigo Company disclosed 2 risk factors in its most recent earnings report. Perrigo Company reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksPerrigo Company Peers Comparison
Overall Rating
VTRS67Neutral
RDY66Neutral
TEVA65Neutral
HLN62Neutral
AMRX58Neutral
PRGO56Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 67Neutral | $23.44B | -38.69 | -4.24% | 2.35% | 4.80% | 82.97% | |
| 66Neutral | $12.37B | 41.31 | 7.37% | 0.76% | -10.52% | -55.45% | |
| 65Neutral | $49.04B | 100.35 | 9.18% | ― | 2.99% | -28.63% | |
| 62Neutral | $39.63B | 18.87 | 9.89% | 1.37% | 4.99% | 12.37% | |
| 58Neutral | $7.36B | 48.70 | 131.71% | ― | 8.88% | 2272.07% | |
| 56Neutral | $2.19B | -1.25 | -68.13% | 7.36% | -4.45% | -3289.03% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRGO | Perrigo Company | 15.76 | 4.04 | 34.53% | |
| RDY | Dr. Reddy's Laboratories Ltd | 14.79 | 0.82 | 5.85% | |
| VTRS | Viatris, Inc. | 20.45 | 10.35 | 102.46% | |
| TEVA | Teva Pharmaceutical Industries Limited | 42.62 | 16.62 | 63.92% | |
| AMRX | Amneal Pharma | 21.12 | 9.60 | 83.33% | |
| HLN | Haleon PLC Sponsored ADR | 9.05 | -0.28 | -3.01% |
Perrigo Company Corporate Events
Perrigo to Divest Infant Formula Business, Refocus Strategy
NeutralOn October 29, 2026, Perrigo announced that it had entered into a definitive agreement to sell its Infant Formula business, signaling a strategic move to reshape its portfolio and sharpen focus on core consumer self-care operations. The divestiture i...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
